Aspire Pharma Acquires Canute To Grow Dermatology & Allergy Lines

Aspire Pharma Limited, a fast-growing UK company specializing in niche generic medications, has expanded its product offerings by acquiring all assets from Canute Pharma Limited. This acquisition not only strengthens Aspire's dermatology portfolio but also paves the way for growth in the UK market by adding new therapeutic categories.

Through this deal, Aspire gains distribution rights for unique products in haptens (allergens) and test chambers used in diagnosing contact dermatitis. The acquisition also includes a topical antibiotic gel for acne treatment and several 'special' products tailored for individual patient needs. Canute Pharma's facility in Knutsford, Cheshire, will now serve as a key distribution hub for Aspire's expanded portfolio. 

Richard Condon, Chief Executive Officer of Aspire, stated“We are delighted to announce the asset purchase from Canute Pharma. It brings a number of innovative products, which will strengthen our commitment to providing high-quality skincare solutions to patients, as well as open-up some opportunities for new areas of growth in the UK and other geographic territories. 

He further continued, “We now look forward to integrating these differentiated product lines, which offer a synergistic fit, into our portfolio. This further supports our commitment to addressing the unmet needs of patients, while delivering true value to healthcare professionals, payors and the NHS.” 

Richard Anderson, Owner and Director of Canute Pharma, mentioned,  “We are pleased to complete the asset sale with Aspire Pharma, which provides consistency for existing distribution arrangements, as well as a good fit in terms of shared values and therapeutic focus that will help continue to improve patient access to essential treatments.”